Английская Википедия:Abbott Laboratories v. Gardner
Шаблон:More citations needed Шаблон:Use mdy dates
Шаблон:Infobox SCOTUS case Шаблон:Wikisource Abbott Laboratories v. Gardner, 387 U.S. 136 (1967), was a case heard before the United States Supreme Court. The Court held that drug companies were not prohibited by the ripeness doctrine from challenging a U.S. Food and Drug Administration (FDA) regulation requiring a prescription drug's generic name to appear on all related printed materials. The government argued that the case was not ripe because the regulation had yet to be enforced. That argument failed as the Court found the issues to be fit for judicial resolution, and that the drug companies would experience substantial hardship if denied a pre-enforcement challenge to the statute. Prosecution for non-compliance was likely, civil and criminal penalties could be imposed, and the drug companies would suffer reputational damage if required to violate the regulation before challenging it in court.
Facts
The action was brought by individuals and associations accounting for more than 90% of the prescription drug industry.Шаблон:Cn Specifically, the petitioners challenged the decision by the Commissioner of Food and Drug to promulgate the "established name" rule pursuant to a statute granted by Congress. After inviting and considering comments submitted by interested parties, the Commissioner established the following rule:
External links
- Английская Википедия
- United States Supreme Court cases
- United States Supreme Court cases of the Warren Court
- United States administrative case law
- 1967 in United States case law
- Abbott Laboratories
- United States ripeness case law
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
